Endoradiotherapy in cancer treatment — Basic concepts and future trends

Zoller, Frederic; Eisenhut, Michael; Haberkorn, Uwe; Mier, Walter

doi:10.1016/j.ejphar.2009.05.035

Cited by 50 publications

(40 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The choice of the radionuclide depends on nuclear emission properties, physical half-life, decay characteristics, availability, cost of the target and production [1]. Quite a few radionuclides useful for therapy have been reported till now [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

New separation method of no-carrier-added ⁴⁷Sc from titanium targets

et al. 2012

View full text Add to dashboard Cite

Scandium radionuclides / Sc-47 radiobioconjugates / Radionuclide therapy Summary. Radionuclides with medium energy beta emission and a several day half-life are attractive candidates for radioimmunotherapy. Among the most promising in this category is 47 Sc produced by fast neutron irradiation (E n > 1 MeV) of titanium target with high energy neutrons in 47 Ti(n, p) 47 Sc nuclear reaction. In the previously reported production scheme the dissolution of the TiO 2 target in hot concentrated H 2 SO 4 and evaporation of the resulting solution were the most timeconsuming steps. The present paper describes new, simple and efficient production method of 47 Sc, where the slow dissolution of the target is avoided. After irradiation in fast neutron flux 47 TiO 2 and Li 2 47 TiF 6 targets were dissolved in HF solutions. Next 47 Sc was separated from the target using anion exchange resin Dowex 1 with 0.4 M HF + 0.06 M HNO 3 solution as eluent. The eluted 47 Sc was adsorbed on cation exchange resin and eluted with 0.5 M of ammonium acetate. The 47 Sc separation yield in the proposed procedure is about 90% with the separation time less than 2 h. The obtained nocarrier-added 47 Sc was used to label DOTATATE conjugate with 96% labeling yield.

show abstract

Section: Introductionmentioning

confidence: 99%

New separation method of no-carrier-added ⁴⁷Sc from titanium targets

et al. 2012

View full text Add to dashboard Cite

show abstract

“…It is based on the use of particle-emitting radioisotopes (e.g., 177 Lu, 90 Y, 131 I) in conjunction with tumortargeted biomolecules (e.g., peptides, antibodies; ref. 1). A prominent example of a successfully used radiopharmaceutical in clinical routine are somatostatin-based radiopeptides (e.g., 177 Lu-DOTATATE, 90 Y-DOTATOC) for the treatment of neuroendocrine tumors (2).…”

Section: Introductionmentioning

confidence: 99%

177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy

Reber

Haller

Leamon

et al. 2013

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Targeted radionuclide therapy has shown impressive results for the palliative treatment of several types of cancer diseases. The folate receptor has been identified as specifically associated with a variety of frequent tumor types. Therefore, it is an attractive target for the development of new radionuclide therapies using folatebased radioconjugates. Previously, we found that pemetrexed (PMX) has a favorable effect in reducing undesired renal uptake of radiofolates. Moreover, PMX also acts as a chemotherapeutic and radiosensitizing agent on tumors. Thus, the aim of our study was to investigate the combined application of PMX and the therapeutic radiofolate 177 Lu-EC0800. Determination of the combination index (CI) revealed a synergistic inhibitory effect of 177 Lu-EC0800 and PMX on the viability of folate receptor-positive cervical (KB) and ovarian (IGROV-1) cancer cells in vitro (CI < 0.8). In an in vivo study, tumor-bearing mice were treated with 177 Lu-EC0800 (20 MBq) and a subtherapeutic (0.4 mg) or therapeutic amount (1.6 mg) of PMX. Application of 177 Lu-EC0800 with PMX ther resulted in a two-to four-fold enhanced tumor growth delay and a prolonged survival of KB and IGROV-1 tumor-bearing mice, as compared to the combination with PMX subther or untreated control mice. PMX subther protected the kidneys from undesired side effects of 177 Lu-EC0800 (20 MBq) by reducing the absorbed radiation dose. Intact kidney function was shown by determination of plasma parameters and quantitative single-photon emission computed tomography using 99m Tc-DMSA. Our results confirmed the anticipated dual role of PMX. Its unique features resulted in an improved antitumor effect of folate-based radionuclide therapy and prevented undesired radio-nephrotoxicity. Mol Cancer Ther; 12(11); 2436-45. Ó2013 AACR.

show abstract

“…[62][63][64][65] Endoradiotherapy is a versatile nuclear medicine application using ionizing radiation for the treatment of manifold diseases, such as cancer or rheumatoid arthritis. [64][65][66] The major advantage of endoradiotherapy compared to other forms of cancer therapy is the possibility to determine the selective accumulation in the targeted tissue by molecular imaging studies via single photon computed tomography (SPECT) or positron emission tomography (PET) using structural identical diagnostic compounds. The targeting of epitopes that are expressed in very low concentrations is feasible.…”

Section: Brachythrapymentioning

confidence: 99%

External and internal radiation therapy: Past and future directions

2010

View full text Add to dashboard Cite

Cancer is a leading cause of morbidity and mortality in the modern world. Treatment modalities comprise radiation therapy, surgery, chemotherapy and hormonal therapy. Radiation therapy can be performed by using external or internal radiation therapy. However, each method has its unique properties which undertakes special role in cancer treatment, this question is brought up that: For cancer treatment, whether external radiation therapy is more efficient or internal radiation therapy one? To answer this question, we need to consider principles and structure of individual methods. In this review, principles and application of each method are considered and finally these two methods are compared with each other.

show abstract

Endoradiotherapy in cancer treatment — Basic concepts and future trends

Cited by 50 publications

References 63 publications

New separation method of no-carrier-added ⁴⁷Sc from titanium targets

New separation method of no-carrier-added ⁴⁷Sc from titanium targets

177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy

External and internal radiation therapy: Past and future directions

Contact Info

Product

Resources

About

Endoradiotherapy in cancer treatment — Basic concepts and future trends

Cited by 50 publications

References 63 publications

New separation method of no-carrier-added 47Sc from titanium targets

New separation method of no-carrier-added 47Sc from titanium targets

177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy

External and internal radiation therapy: Past and future directions

Contact Info

Product

Resources

About

New separation method of no-carrier-added ⁴⁷Sc from titanium targets

New separation method of no-carrier-added ⁴⁷Sc from titanium targets